CN1794987B - 具有提高的抗炎、抗血栓形成和抗血小板活性的作为降胆固醇药的氟伐他汀、普伐他汀、西立伐他汀、阿托伐他汀和罗苏伐他汀的硝基氧基衍生物 - Google Patents
具有提高的抗炎、抗血栓形成和抗血小板活性的作为降胆固醇药的氟伐他汀、普伐他汀、西立伐他汀、阿托伐他汀和罗苏伐他汀的硝基氧基衍生物 Download PDFInfo
- Publication number
- CN1794987B CN1794987B CN2004800144981A CN200480014498A CN1794987B CN 1794987 B CN1794987 B CN 1794987B CN 2004800144981 A CN2004800144981 A CN 2004800144981A CN 200480014498 A CN200480014498 A CN 200480014498A CN 1794987 B CN1794987 B CN 1794987B
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- formula
- fluvastatin
- pravastatin
- nitrooxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
化合物 | IC<sub>50</sub>(μM)±sem |
普伐他汀 | >30 |
实施例1的化合物 | 2.4±0.6 |
氟伐他汀 | >30 |
实施例3的化合物 | 13.4±3.5 |
实施例4的化合物 | 8.7±3.3 |
化合物 | 浓度(μM) | iNOS(%减少vs LPS) | COX2(%减少vs LPS) |
氟伐他汀 | 10 | -14.8±5.9 | -2.8±3.7 |
实施例3中化合物 | 10 | 44.8±11.9 | 53.9±6.1 |
实施例4中化合物 | 10 | 22.4±9.6 | 19.4±6.5 |
普伐他汀 | 100 | 4.7±3.6 | 26.9±7.9 |
实施例1的化合物 | 100 | 55.2±11.8 | 74.9±4.4 |
阿托伐他汀 | 10 | 20±14 | - |
实施例7中化合物 | 10 | 45±9 | - |
化合物 | N毛细管/mm<sup>2</sup>在局部缺血的内收肌中 | N毛细管/mm<sup>2</sup>在对侧的内收肌中 |
赋形剂 | 852±32<sup>§§</sup> | 685±38 |
普伐他汀 | 823±42 | 736±40 |
实施例1的化合物 | 1116±53<sup>§§**++</sup> | 660±40 |
化合物 | ApoE敲除小鼠白细胞粘附性(%)(胸主动脉) |
赋形剂 | 23.4±5 |
普伐他汀 | 23.0±6 |
实施例1的化合物 | 9.3±3<sup>*</sup># |
化合物 | 抗血栓形成活性(%)攻击前1-h | 抗血栓形成活性(%)攻击前3-h |
赋形剂 | 0 | 0 |
普伐他汀10mg/kg腹腔注射20mg/kg腹腔注射 | 1525 | 1020 |
实施例1的化合物12mg/kg腹腔注射24mg/kg腹腔注射 | 30<sup>*</sup>40<sup>*</sup> | 40<sup>*</sup>50<sup>*</sup> |
化合物 | 血小板凝聚(GFP)IC<sub>50</sub>μM | 血小板凝聚(PRP)IC<sub>50</sub>μM |
普伐他汀 | >200 | >200 |
实施例1的化合物 | 101±10 | 74±7 |
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03101530 | 2003-05-27 | ||
EP03101530.8 | 2003-05-27 | ||
PCT/EP2004/050897 WO2004105754A1 (en) | 2003-05-27 | 2004-05-24 | Nitrooxyderivatives of fluvastatin, pravastatin, cerivastatin, atorvastatin and rosuvastatin as cholesterol-reducing agents with improved anti-inflammatory, antithrombotic and antiplatelet activity |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1794987A CN1794987A (zh) | 2006-06-28 |
CN1794987B true CN1794987B (zh) | 2010-09-29 |
Family
ID=33483985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800144981A Expired - Fee Related CN1794987B (zh) | 2003-05-27 | 2004-05-24 | 具有提高的抗炎、抗血栓形成和抗血小板活性的作为降胆固醇药的氟伐他汀、普伐他汀、西立伐他汀、阿托伐他汀和罗苏伐他汀的硝基氧基衍生物 |
Country Status (23)
Country | Link |
---|---|
US (4) | US7166638B2 (zh) |
EP (1) | EP1626716B1 (zh) |
KR (1) | KR101136434B1 (zh) |
CN (1) | CN1794987B (zh) |
AR (1) | AR044561A1 (zh) |
AT (1) | ATE353214T1 (zh) |
AU (1) | AU2004243443B2 (zh) |
BR (1) | BRPI0410049A (zh) |
CA (1) | CA2527168C (zh) |
CY (1) | CY1107614T1 (zh) |
DE (1) | DE602004004652T2 (zh) |
DK (1) | DK1626716T3 (zh) |
ES (1) | ES2280978T3 (zh) |
HK (1) | HK1090295A1 (zh) |
MX (1) | MXPA05012755A (zh) |
NO (1) | NO20056152L (zh) |
NZ (1) | NZ543086A (zh) |
PL (1) | PL379019A1 (zh) |
PT (1) | PT1626716E (zh) |
RU (1) | RU2362770C2 (zh) |
SI (1) | SI1626716T1 (zh) |
WO (1) | WO2004105754A1 (zh) |
ZA (1) | ZA200509460B (zh) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007002210A (es) | 2004-08-26 | 2007-05-07 | Nicholas Piramal India Ltd | Profarmacos que contienen enlazantes bioescindibles novedosos. |
TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
CN101378739B (zh) | 2006-02-03 | 2014-06-04 | 尼科克斯公司 | 药物的硝基氧基衍生物用于治疗肌肉营养不良症的应用 |
EP1889617A1 (en) * | 2006-07-11 | 2008-02-20 | Freie Universität Berlin | Triphenyl modified 5-membered heterocycles and their use as anticancer and antiflammatory agents |
CN101668740A (zh) * | 2007-04-13 | 2010-03-10 | 尼科克斯公司 | “阿托伐他汀4-(硝基氧基)丁基酯的结晶形式” |
WO2009000592A1 (en) * | 2007-06-25 | 2008-12-31 | Nicox S.A. | Use of nitric oxide-releasing statins in the treatment of pulmonary arterial hypertension |
US20090226515A1 (en) * | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Statin compositions |
JP2011521992A (ja) * | 2008-06-06 | 2011-07-28 | ニコックス エス エイ | アトルバスタチン4−(ニトロキシ)ブチルエステルおよび脂質低下剤を含む組成物 |
US7807716B2 (en) * | 2008-09-24 | 2010-10-05 | Oral Delivery Technology Ltd. | Nitric oxide amino acid ester compound, compositions for increasing nitric oxide levels and method of use |
CN101613284B (zh) * | 2009-06-26 | 2013-05-08 | 四川抗菌素工业研究所有限公司 | 洛伐他汀、辛伐他汀和辛伐他汀-6-氧化物的硝基氧基衍生物及其制备方法 |
EP2371404A3 (de) | 2010-03-30 | 2014-08-20 | Biotronik AG | Medizinisches Implantat mit einer Beschichtung bestehend aus oder enthaltend mindestens einen Nitro-Statin-Wirkstoff |
WO2011160974A2 (en) | 2010-06-21 | 2011-12-29 | Nicox S.A. | Statin derivatives |
WO2014111957A1 (en) | 2013-01-21 | 2014-07-24 | Apparao Satyam | Nitric oxide releasing prodrugs of therapeutic agents |
WO2014168933A1 (en) | 2013-04-08 | 2014-10-16 | Cytodyn Inc. | Felinized antibodies and methods of treating retroviral infections in felines |
EP2949324A1 (en) | 2014-05-27 | 2015-12-02 | Consorci Institut Catala de Ciencies Cardiovasculars | Prevention and/or treatment of ischemia/reperfusion injury |
CN104327057B (zh) * | 2014-10-17 | 2017-01-18 | 上海应用技术学院 | 多取代吲哚类他汀内酯脱水化合物及其用途 |
US10456405B2 (en) | 2015-09-07 | 2019-10-29 | Zhejiang Huahai Pharmaceutical Co., Ltd | Nitric oxide-releasing prodrug molecule of substituted quinazolines |
CN108114282B (zh) * | 2016-11-28 | 2021-03-02 | 北京大学第三医院 | 他汀类化合物治疗缺血性疾病的用途 |
CN107098843B (zh) * | 2017-03-31 | 2020-04-28 | 中国医药集团总公司四川抗菌素工业研究所 | 一种fk409类no供体型他汀降血脂药物衍生物及其制备方法 |
CN107043373B (zh) * | 2017-03-31 | 2020-04-28 | 中国医药集团总公司四川抗菌素工业研究所 | 一种噁三唑类no供体型他汀衍生物及其制备方法和应用 |
CN106938979B (zh) * | 2017-03-31 | 2019-08-02 | 中国医药集团总公司四川抗菌素工业研究所 | 一种no供体型他汀衍生物、制备方法和应用 |
EP3381452A1 (en) | 2017-03-31 | 2018-10-03 | Instituto Catalán de Ciencias Cardiovasculares (ICCC), Hospital de la Santa Creu i Sant Pau, Avda. | Statin for prevention/reduction of ischemia-related damage |
ES2877646T3 (es) | 2017-03-31 | 2021-11-17 | Fundacio Inst De Recerca De Lhospital De La Santa Creu I Sant Pau | Estatina para la prevención o reducción de los daños relacionados con la isquemia |
CN110183329B (zh) * | 2019-06-19 | 2022-09-13 | 中国医药集团总公司四川抗菌素工业研究所 | 硝酸酯类no供体型他汀衍生物及其制备方法 |
CN113929609A (zh) * | 2021-10-13 | 2022-01-14 | 深圳弘汇生物医药有限公司 | 一种调血脂的阿托伐他汀衍生物及其组合物、制备方法和医药用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997016405A1 (en) * | 1995-10-31 | 1997-05-09 | Nicox S.A. | New compounds and their compositions having anti-inflammatory and anti-thrombotic activities |
CN1358178A (zh) * | 1999-04-13 | 2002-07-10 | 尼科克斯公司 | 药用化合物 |
WO2003007846A1 (en) * | 2001-07-19 | 2003-01-30 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
WO1997013405A1 (en) * | 1995-10-13 | 1997-04-17 | The United States Of America, Represented By The Secretary Of Agriculture | In ovo yeast treatment to diminish salmonellae populations in poultry |
IT1295694B1 (it) | 1996-11-14 | 1999-05-27 | Nicox Sa | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica |
IT1311924B1 (it) | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
IT1314184B1 (it) | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
US6573385B1 (en) * | 1999-11-11 | 2003-06-03 | Biocon India Limited | Process for manufacturing simvastatin and novel intermediates thereof |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
-
2004
- 2004-05-20 US US10/849,561 patent/US7166638B2/en not_active Expired - Fee Related
- 2004-05-24 DK DK04741636T patent/DK1626716T3/da active
- 2004-05-24 WO PCT/EP2004/050897 patent/WO2004105754A1/en active IP Right Grant
- 2004-05-24 NZ NZ543086A patent/NZ543086A/en not_active IP Right Cessation
- 2004-05-24 AU AU2004243443A patent/AU2004243443B2/en not_active Ceased
- 2004-05-24 EP EP04741636A patent/EP1626716B1/en not_active Expired - Lifetime
- 2004-05-24 PL PL379019A patent/PL379019A1/pl not_active Application Discontinuation
- 2004-05-24 RU RU2005138139/04A patent/RU2362770C2/ru not_active IP Right Cessation
- 2004-05-24 ES ES04741636T patent/ES2280978T3/es not_active Expired - Lifetime
- 2004-05-24 CA CA2527168A patent/CA2527168C/en not_active Expired - Fee Related
- 2004-05-24 DE DE602004004652T patent/DE602004004652T2/de not_active Expired - Lifetime
- 2004-05-24 KR KR1020057022246A patent/KR101136434B1/ko not_active IP Right Cessation
- 2004-05-24 BR BRPI0410049-2A patent/BRPI0410049A/pt not_active IP Right Cessation
- 2004-05-24 PT PT04741636T patent/PT1626716E/pt unknown
- 2004-05-24 AT AT04741636T patent/ATE353214T1/de active
- 2004-05-24 CN CN2004800144981A patent/CN1794987B/zh not_active Expired - Fee Related
- 2004-05-24 SI SI200430242T patent/SI1626716T1/sl unknown
- 2004-05-24 MX MXPA05012755A patent/MXPA05012755A/es active IP Right Grant
- 2004-05-26 AR ARP040101813A patent/AR044561A1/es not_active Application Discontinuation
-
2005
- 2005-11-22 ZA ZA200509460A patent/ZA200509460B/en unknown
- 2005-12-23 NO NO20056152A patent/NO20056152L/no not_active Application Discontinuation
-
2006
- 2006-10-09 HK HK06111070.4A patent/HK1090295A1/xx not_active IP Right Cessation
- 2006-11-01 US US11/590,770 patent/US7297808B2/en not_active Expired - Fee Related
-
2007
- 2007-04-13 CY CY20071100515T patent/CY1107614T1/el unknown
- 2007-10-05 US US11/905,910 patent/US7563909B2/en not_active Expired - Fee Related
- 2007-10-05 US US11/905,893 patent/US7462716B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997016405A1 (en) * | 1995-10-31 | 1997-05-09 | Nicox S.A. | New compounds and their compositions having anti-inflammatory and anti-thrombotic activities |
CN1358178A (zh) * | 1999-04-13 | 2002-07-10 | 尼科克斯公司 | 药用化合物 |
WO2003007846A1 (en) * | 2001-07-19 | 2003-01-30 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1794987B (zh) | 具有提高的抗炎、抗血栓形成和抗血小板活性的作为降胆固醇药的氟伐他汀、普伐他汀、西立伐他汀、阿托伐他汀和罗苏伐他汀的硝基氧基衍生物 | |
AU601981B2 (en) | Trans- (2-(3 or 4-carboxamido-substituted pyrrol-1-yl) alkyl)-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | |
US4256751A (en) | Tetrahydroisoquinoline derivatives | |
JP6155395B2 (ja) | 新規dgat2阻害剤 | |
JPS62103065A (ja) | ピリジン誘導体 | |
EP3348548A1 (en) | Nitric oxide-releasing prodrug molecule | |
WO2005115397A2 (en) | Compositions and treatments for modulating kinase and/or hmg-coa reductase | |
JPH04221327A (ja) | スクアレンエポキシダーゼの抑制剤としてのスクアレンのジ−及びテトラ−フルオロ類似体類 | |
AU777377B2 (en) | Dibenzo(a,g)quinolizinium derivatives and the salts thereof | |
JPH02229168A (ja) | ピラゾロン誘導体 | |
JPH01135783A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
US10800733B2 (en) | Acetophenone compound, preparation method therefor, and application thereof in blood lipid regulation | |
JP2002201127A (ja) | ウレア誘導体 | |
JP2595931B2 (ja) | 2,5−ピロリジンジオン誘導体及びその製法 | |
JPS6165870A (ja) | ピラゾールジオン誘導体及びその使用 | |
US20040048909A1 (en) | Biphenyl derivatives | |
JP2564781B2 (ja) | 2,5−ピロリジンジオン誘導体及びその製法 | |
US5164505A (en) | N-phenyl-N'-alkyl-N'-pyridylmethyl-bis-diamino-5-methylene-1,3-dioxane-4,6-diones | |
JP2541420B2 (ja) | 3−ブテン酸誘導体及びその製法 | |
JPH02311479A (ja) | キノリン誘導体 | |
JPH0733660A (ja) | 脂質代謝改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1090295 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1090295 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: NICOX SCIENCE IRELAND LIMITED Free format text: FORMER OWNER: NICOX S.A. Effective date: 20141021 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20141021 Address after: Dublin, Ireland Patentee after: Ireland Nikekesi science company Address before: France Sophia bntipolis - Wahl Bonet Patentee before: Nicox S. A. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100929 Termination date: 20160524 |
|
CF01 | Termination of patent right due to non-payment of annual fee |